Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.82)
# 3,620
Out of 4,667 analysts
35
Total ratings
42.86%
Success rate
0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterates: Neutral | n/a | $71.05 | - | 5 | Nov 19, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $9.64 | - | 3 | Nov 14, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | n/a | $18.38 | - | 1 | Oct 8, 2024 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $54.62 | - | 3 | Sep 20, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $43.65 | +119.93% | 4 | Sep 18, 2024 | |
| BLUE bluebird bio | Reiterates: Neutral | n/a | $0.30 | - | 2 | Sep 16, 2024 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $7.80 | - | 3 | Sep 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Overweight | n/a | $32.42 | - | 2 | Sep 9, 2024 | |
| BIIB Biogen | Reiterates: Overweight | $292 | $156.00 | +87.18% | 3 | Sep 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $47.26 | - | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.08 | - | 2 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $1.98 | - | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $451.23 | -18.00% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.41 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.04 | - | 1 | May 30, 2017 |
Incyte
Nov 19, 2024
Reiterates: Neutral
Price Target: n/a
Current: $71.05
Upside: -
Alumis
Nov 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.64
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $18.38
Upside: -
Agios Pharmaceuticals
Sep 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.62
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $43.65
Upside: +119.93%
bluebird bio
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.30
Upside: -
Immatics
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.80
Upside: -
Immunocore Holdings
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $32.42
Upside: -
Biogen
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $156.00
Upside: +87.18%
CRISPR Therapeutics AG
Aug 8, 2024
Reiterates: Neutral
Price Target: n/a
Current: $47.26
Upside: -
Jul 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.08
Upside: -
May 30, 2024
Initiates: Overweight
Price Target: n/a
Current: $1.98
Upside: -
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $451.23
Upside: -18.00%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.41
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -